MLTX Stock — MoonLake Immunotherapeutics: Metrics

Market overview

2 metrics

Share price

$15.06

Market cap

$1.29B

Price action

19 metrics

Price change (1W)

-2.8%

Price change (30D)

-13.0%

Price change (3M)

-15.3%

Price change (6M)

-14.5%

Price change (YTD)

+14.8%

Price change (1Y)

-72.9%

Trailing year

Price change (5Y)

+53.1%

52-week high

$61.99

52-week low

$6.25

Change from 52-week high

-75.6%

Change from 52-week low

+142.3%

Annualized volatility

117.9%

Beta

1.2

RSI (14D)

34.5

Price vs SMA 50

-16.6%

Price vs SMA 200

-10.3%

Avg volume (3M)

1.24M

Relative volume

0.5

Average dollar volume

$22.89M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

85.11M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

3.0

reciprocal yield 33.3%

FCF yield

-17.5%

TTM · current market cap

Buyback yield

0.0%

P / FCF

—

P / operating cash flow

—

Earnings yield

-20.4%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

0.0%

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-02-23

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$268.33M

Net income (TTM)

−$263.05M

Trailing 12 months

Diluted EPS (TTM)

$-3.85

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-1.68

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

—

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+16.8%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-61.4%

Return on assets

-45.8%

Debt / equity

—

Current ratio

12.6

EBITDA (TTM)

—

Free cash flow (TTM)

−$225.18M

Quick ratio

12.6

Interest coverage

-26.6

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

$477.90M

Total assets

$573.95M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$225.18M

Capital expenditures (TTM)

$0

R&D (TTM)

$221.38M

SG&A (TTM)

—

Stock compensation (TTM)

$23.20M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

176

13F filer change QoQ

+27

Institutional ownership

88.4%

Short interest

3 metrics

Short interest

8.0%

Latest settlement · 4.2 days to cover

Days to cover

4.2d

Short-squeeze score

57 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$9.34M

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

MLTX · MoonLake Immunotherapeutics

MLTX metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search